Charles River Laboratories Announces Plan to Construct New Preclinical Services Facility in Quebec

    WILMINGTON, MASS., August 27 /CNW/ - Charles River Laboratories
International, Inc. (NYSE:   CRL) announced today that it intends to build a new
facility in Sherbrooke, Quebec, to support the company's expanding Preclinical
Services business. Located in the newly constructed Sherbrooke Biomedical
Park, Charles River's newest facility will provide essential drug discovery
and development services to the international pharmaceutical and
biopharmaceutical industries.

    When completed, the new facility will be approximately 300,000 square
feet. Approximately 25 percent will be constructed in the first phase and is
expected to be dedicated to one or two clients. The first phase is scheduled
to be opened by the first quarter of 2009. Timing of construction of the
remaining phases will be dependent on market demand. The Sherbrooke facility
is ultimately expected to employ 1,000 people, who will work collaboratively
with the 1,600 staff currently located in the company's Montreal facility.

    James C. Foster, Chairman, President and Chief Executive Officer of
Charles River Laboratories said, "We are very pleased to add this new project
to our Preclinical Services expansion program. As customers choose strategic
outsourcing as a means to improve the drug development process, they are
increasingly turning to Charles River for our scientific expertise and the
high-quality preclinical services we provide. This new facility will enable us
to continue to support that demand from our global customers."

    "Our goal was to identify a location similar to Montreal, equally
convenient for our customers, where we could situate this new facility.
Sherbrooke is ideal for many reasons, including its proximity to world-class
educational institutions offering well-educated laboratory and life sciences
graduates, as well as opportunities for collaborations and access to
cutting-edge technology," said Christopher Perkin, Corporate Vice President
and President, Canadian Preclinical Services. "We greatly appreciate the
assistance of the government of Quebec, which is supporting this project, as
we support our customers' efforts to bring drugs to market faster and more
cost effectively."

    Caution Concerning Forward-Looking Statements

    This news release includes forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements may be identified by the use of words such as "anticipate,"
"believe," "expect," "will," "may," "estimate," "plan," "outlook," and
"project" and other similar expressions that predict or indicate future events
or trends or that are not statements of historical matters. Forward-looking
statements include the statements in this press release regarding Charles
River's expectation regarding the construction of a new facility in Canada,
including the timing of facility construction and eventual staffing levels,
the likelihood of dedicated space arrangements, and future demand for products
and services provided by Charles River at this facility. Forward-looking
statements are based on Charles River's current expectations and beliefs, and
involve a number of risks and uncertainties that are difficult to predict and
that could cause actual results to differ materially from those stated or
implied by the forward-looking statements. A further description of these
risks, uncertainties, and other matters can be found in the Risk Factors
detailed in Charles River's Annual Report on Form 10-K as filed on February
27, 2007, as well as other filings we make with the Securities and Exchange
Commission. Charles River assumes no obligation and expressly disclaims any
duty to update information contained in this release except as required by

    About Charles River Laboratories

    Charles River Laboratories based in Wilmington, Massachusetts, partners
with global pharmaceutical and biotechnology companies, government agencies
and leading academic institutions to advance the drug discovery and
development process, bringing drugs to market faster and more efficiently.
Charles River's 8,000 employees serve clients worldwide. For more information
on Charles River, visit our website at

For further information:

For further information: Charles River Laboratories Investors: Susan E.
Hardy, 781-262-7616 Corporate Vice President, Investor Relations or Todd
Spencer, 781-262-7692 Manager, Investor Relations Charles River Laboratories
or Media: Amy Cianciaruso, 978-658-6000 Ext. 1878 Associate Director, Public

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890